Cost-effectiveness of lowering blood pressure with a fixed combination of perindopril and indapamide in type 2 diabetes mellitus: an ADVANCE trial-based analysis

Objective: to determine the cost-effectiveness of routine administration, irrespective of blood pressure (BP), of a fixed-dose combination of perindopril and indapamide to patients with type 2 diabetes mellitus Design, setting and participants: Prospective cost-effectiveness analysis within the Action in Diabetes and Vascular Disease Preterax and Diamicron-MR Controlled Evaluation (ADVANCE) trial, an international, multicentre, randomised controlled trial of 11 140 participants with type 2 diabetes randomly allocated to receive perindopril plus indapamide (4 mg-1 25 mg/day) or placebo Main outcome measures: Health-related quality-of-life measured by the EuroQol-5D, resource utilisation, and cost-effectiveness (cost per death averted at 4 3 years' average follow-up, and estimated cost per life-year gained, by extrapolation) Results: The mean health-related quality-of-life score of survivors was 080 (on a 0-1 scale [death to full health]), with no difference between treatment groups Active treatment reduced hospital admissions for coronary heart disease and coronary revascularisation by 5% For the Australian participants, perindopril indapamide cost A$1368 per patient during the trial period, but reduced total hospitalisation costs by A$410 and other medication costs (mainly other BP-lowering drugs) by A$332 The absolute reduction in all-cause mortality for the active treatment group was 1 1%, giving a cost per life saved of A$49200 Lifetime extrapolation gave an estimated cost per life-year saved of A$10 040 (discounted at 5% per year) Conclusion: The combination of perindopril and indapamide in patients with type 2 diabetes appears to be cost-effective